TLV reconsiders subsidy of CGRP inhibitors

18 May 2022 - TLV has started a review of the CGRP inhibitors. ...

Read more →

Health economic assessment of Xevudy for the treatment of COVID-19

17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab).  ...

Read more →

Tepmetko is granted a temporary subsidy

16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...

Read more →

Health economic assessment of Abecma in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel).  ...

Read more →

Health economic assessment of Blenrep in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin).  ...

Read more →

New handbook on health economic assessments of medical devices

4 May 2022 - TLV performs health economic assessments of medical technology products at the request of the Medical Technology Product ...

Read more →

Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders

26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...

Read more →

Final reconciliation of savings from side agreements for the full year 2021

18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...

Read more →

Annual report 2021: more Government assignments and increased EU cooperation on TLV

23 February 2022 - In 2021, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reported a number of urgent government assignments ...

Read more →

Health economic assessment of the gene therapy Libmeldy in metachromatic leukodystrophy

22 February 2022 - Within the FINOSE collaboration, TLV, together with the corresponding authorities in Finland and Norway, has produced a ...

Read more →

Health economic assessment of Jemperli in endometrial cancer

11 February 2022 - TLV has produced a health economic assessment for the regions for the drug Jemperli (dostarlimab) which is ...

Read more →

Health economic assessment of Adakveo for the treatment of sickle cell anaemia

11 February 2022 - Adakveo is used to prevent recurrent so-called vaso-occlusive crises in patients from 16 years of age who ...

Read more →

Health economic assessment of Opdivo in cancer of the oesophagus or upper gastro-intestinal tract

7 February 2022 - TLV has produced a health economic assessment for the regions for Opdivo (nivolumab).  ...

Read more →

Weak krona exchange rates result in lower drug prices

3 February 2022 - The price of medicines in Sweden has fallen compared with other countries and is among the lowest ...

Read more →

The price of cystic fibrosis drugs is still too high

27 January 2022 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has decided that Kaftrio and Kalydeco for cystic fibrosis ...

Read more →